Declared Dividend • Jul 13
Dividend reduced to CN¥0.20 Dividend of CN¥0.20 is 60% lower than last year. Ex-date: 17th July 2026 Payment date: 17th July 2026 Dividend yield will be 1.5%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is well covered by cash flows (27% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years. However, payments have been volatile during that time. Announcement • Jun 30
Sunflower Pharmaceutical Group Co.,Ltd to Report First Half, 2026 Results on Aug 29, 2026 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report first half, 2026 results on Aug 29, 2026 Board Change • May 20
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Jianzhong Zhou was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 26
Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 22, 2026 Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 22, 2026, at 13:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China Announcement • Mar 31
Sunflower Pharmaceutical Group Co.,Ltd to Report Q1, 2026 Results on Apr 30, 2026 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 31
Sunflower Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2025 Results on Apr 27, 2026 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report fiscal year 2025 results on Apr 27, 2026 Announcement • Sep 30
Sunflower Pharmaceutical Group Co.,Ltd to Report Q3, 2025 Results on Oct 28, 2025 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q3, 2025 results on Oct 28, 2025 Announcement • Jul 02
Sunflower Pharmaceutical Group Co.,Ltd to Report First Half, 2025 Results on Aug 28, 2025 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • May 24
Sunflower Pharmaceutical Group Co.,Ltd Approves Cash Dividend for 2024 for 2024 Sunflower Pharmaceutical Group Co.,Ltd at its Annual General Meeting of 2024 on 22 May 2025 approved: Cash dividend/10 shares (tax included): CNY 5.00000000 for 2024. Announcement • Apr 25
Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 22, 2025 Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 22, 2025, at 13:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China Announcement • Mar 31
Sunflower Pharmaceutical Group Co.,Ltd to Report Q1, 2025 Results on Apr 25, 2025 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 31
Sunflower Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2024 Results on Apr 25, 2025 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.37 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.37 in 3Q 2023). Revenue: CN¥439.3m (down 63% from 3Q 2023). Net income: CN¥100.5m (down 53% from 3Q 2023). Profit margin: 23% (up from 18% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 14% per year. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥19.77, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total returns to shareholders of 60% over the past three years. Announcement • Sep 30
Sunflower Pharmaceutical Group Co.,Ltd to Report Q3, 2024 Results on Oct 29, 2024 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q3, 2024 results on Oct 29, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥21.73, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 80% over the past three years. Reported Earnings • Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.39 (down from CN¥0.40 in 2Q 2023). Revenue: CN¥1.01b (down 20% from 2Q 2023). Net income: CN¥231.1m (flat on 2Q 2023). Profit margin: 23% (up from 18% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 13% per year. Buy Or Sell Opportunity • Jul 05
Now 22% overvalued Over the last 90 days, the stock has fallen 1.4% to CN¥24.86. The fair value is estimated to be CN¥20.36, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 21%. Board Change • Jul 01
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Non-Independent Director Jianzhong Zhou was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 29
Sunflower Pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Aug 28, 2024 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • Jun 27
Sunflower Pharmaceutical Group Co.,Ltd Announces Board Appointments Sunflower Pharmaceutical Group Co.,Ltd held its 1st Extraordinary General Meeting of 2024 on 25 June 2024, approved the appointment of Zhou Jianzhong, non-independent director, Yang Yang, non-independent director. Zhao Yan, independent director, Zhang Ying, independent director and Miao Jiajun, independent director. Cui Jian, non-employee supervisor. Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥25.16, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 92% over the past three years. Declared Dividend • Jun 07
Dividend increased to CN¥1.50 Dividend of CN¥1.50 is 50% higher than last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 5.0%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is not adequately covered by earnings (90.3% earnings payout ratio) nor is it covered by cash flows (122% cash payout ratio). The dividend has increased by an average of 37% per year over the past 9 years. However, payments have been volatile during that time. Earnings per share has grown by 11% over the last 5 years, which if continued should maintain adequate earnings cover for the dividend. Announcement • Jun 06
Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend (Tax Included) (A Shares) for the Year 2023, Payable on 14 June 2024 Sunflower Pharmaceutical Group Co.,Ltd announced final Cash dividend (tax included) (A shares) for the year 2023 of CNY 15.0000000 per 10 shares. The dividend will be payable on 14 June 2024 with Record date of 13 June 2024 and Ex-date of 14 June 2024. Announcement • Apr 28
Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 30, 2024 Sunflower Pharmaceutical Group Co.,Ltd, Annual General Meeting, May 30, 2024, at 13:00 China Standard Time. Location: The Company's Meeting Room, Harbin, Heilongjiang China Agenda: To consider and approve the 2023 business report; to consider and approve the audit committee report; to consider and approve the private placement of shares; to consider and approve the business report and financial statements; to consider and approve the appropriation of profit and loss; to consider and approve the appointment of audit firm; and to consider and approve any other matters. Announcement • Apr 27
Sunflower Pharmaceutical Group Co.,Ltd Announces Profit Distribution Proposal for 2023 Sunflower Pharmaceutical Group Co.,Ltd announced on 26 April 2024 the profit distribution proposal for 2023 as follows: Cash dividend/10 shares (tax included): CNY 15.00000000. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.44 (vs CN¥0.70 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.44 (down from CN¥0.70 in 1Q 2023). Revenue: CN¥1.52b (down 14% from 1Q 2023). Net income: CN¥255.2m (down 37% from 1Q 2023). Profit margin: 17% (down from 23% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 20% per year. Announcement • Mar 30
Sunflower Pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Dec 29
Sunflower Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Apr 26, 2024 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 26
Third quarter 2023 earnings released: EPS: CN¥0.37 (vs CN¥0.18 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.37 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥1.20b (up 23% from 3Q 2022). Net income: CN¥213.0m (up 98% from 3Q 2022). Profit margin: 18% (up from 11% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Sunflower Pharmaceutical Group Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023 Sunflower Pharmaceutical Group Co.,Ltd announced that they will report Q3, 2023 results on Oct 26, 2023 Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.32 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.40 (up from CN¥0.32 in 2Q 2022). Revenue: CN¥1.27b (up 21% from 2Q 2022). Net income: CN¥232.0m (up 28% from 2Q 2022). Profit margin: 18% (up from 17% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • May 31
Sunflower Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 7, 2023 Sunflower Pharmaceutical Group Co.,Ltd announced Cash dividend/10 shares (tax included): CNY 10.00000000 on share A for 2022. Record date: 06 June 2023, Ex-date: 07 June 2023, Payment date: 07 June 2023. Reported Earnings • Apr 12
Full year 2022 earnings released: EPS: CN¥1.48 (vs CN¥1.21 in FY 2021) Full year 2022 results: EPS: CN¥1.48 (up from CN¥1.21 in FY 2021). Revenue: CN¥5.09b (up 14% from FY 2021). Net income: CN¥867.2m (up 23% from FY 2021). Profit margin: 17% (up from 16% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 18% per year. Buying Opportunity • Mar 23
Now 20% undervalued Over the last 90 days, the stock is up 18%. The fair value is estimated to be CN¥30.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Buying Opportunity • Mar 02
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CN¥30.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Buying Opportunity • Feb 03
Now 21% undervalued Over the last 90 days, the stock is up 3.4%. The fair value is estimated to be CN¥30.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Buying Opportunity • Jan 11
Now 21% undervalued Over the last 90 days, the stock is up 32%. The fair value is estimated to be CN¥31.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 26% share price gain to CN¥25.91, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 99% over the past three years. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥22.51, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 39x in the Pharmaceuticals industry in China. Total returns to shareholders of 79% over the past three years. Buying Opportunity • Dec 10
Now 21% undervalued Over the last 90 days, the stock is up 46%. The fair value is estimated to be CN¥33.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Buying Opportunity • Nov 23
Now 21% undervalued Over the last 90 days, the stock is up 64%. The fair value is estimated to be CN¥36.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 14%. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥29.10, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Total returns to shareholders of 133% over the past three years. Board Change • Nov 16
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Xianwang Shi was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.18 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥980.3m (up 7.3% from 3Q 2021). Net income: CN¥107.9m (up 16% from 3Q 2021). Profit margin: 11% (in line with 3Q 2021). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 16% per year. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥20.44, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 56% over the past three years. Buying Opportunity • Sep 16
Now 21% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be CN¥22.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. Board Change • Sep 07
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Xianwang Shi was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Aug 19
Now 20% undervalued Over the last 90 days, the stock is up 9.6%. The fair value is estimated to be CN¥22.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.14 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.32 (up from CN¥0.14 in 2Q 2021). Revenue: CN¥1.05b (up 19% from 2Q 2021). Net income: CN¥182.0m (up 124% from 2Q 2021). Profit margin: 17% (up from 9.2% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year. Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥16.28, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 11% over the past three years. Reported Earnings • Apr 27
Full year 2021 earnings released: EPS: CN¥1.21 (vs CN¥1.00 in FY 2020) Full year 2021 results: EPS: CN¥1.21 (up from CN¥1.00 in FY 2020). Revenue: CN¥4.46b (up 29% from FY 2020). Net income: CN¥704.7m (up 21% from FY 2020). Profit margin: 16% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥15.93, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total loss to shareholders of 1.5% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥913.5m (up 51% from 3Q 2020). Net income: CN¥93.4m (up 17% from 3Q 2020). Profit margin: 10% (down from 13% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.15 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥885.0m (up 28% from 2Q 2020). Net income: CN¥81.4m (down 1.8% from 2Q 2020). Profit margin: 9.2% (down from 12% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 03
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥17.94, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 5.6% over the past three years. Reported Earnings • Apr 21
Full year 2020 earnings released: EPS CN¥1.00 (vs CN¥0.97 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥3.46b (down 21% from FY 2019). Net income: CN¥584.5m (up 3.4% from FY 2019). Profit margin: 17% (up from 13% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 28
New 90-day low: CN¥12.98 The company is down 16% from its price of CN¥15.50 on 30 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥14.03 The company is down 15% from its price of CN¥16.53 on 14 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 26
New 90-day low: CN¥14.53 The company is down 5.0% from its price of CN¥15.33 on 28 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 12% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥508.9m, down 14% from the prior year. Total revenue was CN¥3.43b over the last 12 months, down 24% from the prior year. 
